PRO-OXAZEPAM 10 MG — DIN 00497754
OXAZEPAM : 10 MG · PRO DOC LIMITEE · TABLET · wholesale supply in Canada
Health Canada status: MARKETED
What is PRO-OXAZEPAM?
PRO-OXAZEPAM 10 MG contains OXAZEPAM : 10 MG. It is listed in the Health Canada Drug Product Database under DIN 00497754, held by PRO DOC LIMITEE, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 18-Jul-2023. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is PRO-OXAZEPAM used for?
PRO-OXAZEPAM (oxazepam tablets) is indicated for the short-term symptomatic relief of excessive anxiety and tension in patients with anxiety neurosis. PRO-OXAZEPAM also is indicated for relieving the symptoms of acute alcoholic withdrawal, including acute agitation and impending delirium tremens.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How much does Oxazepam cost around the world?
Oxazepam is listed on 10 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Australia publishes a ex-manufacturer; Austria publishes a KVP (Kassenverkaufspreis); Czechia publishes a max producer price (ex-factory). Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed | Range |
|---|---|---|---|---|
| Australia | ex-manufacturer | 6 | 28 | AUD███.██ |
| Sweden | AIP (pharmacy purchase price) | 2 | 17 | SEK███.██ |
| South Africa | single exit price | 10 | 13 | ZAR███.██ |
| United States | acquisition | 3 | 12 | USD███.██ |
| Iceland | max wholesale | 1 | 5 | ISK███.██ |
| Austria | KVP (Kassenverkaufspreis) | 3 | 4 | EUR███.██ |
| United Kingdom | hospital | 2 | 2 | GBP███.██ |
| Czechia | max producer price (ex-factory) | 1 | 1 | CZK███.██ |
| Luxembourg | reimbursement | 1 | 1 | EUR███.██ |
| Slovakia | categorised final price | 1 | 1 | EUR███.██ |
84 pack listings across 30 brand entries and 10 price bases, refreshed 08 Sep 2026. Ranges span every Oxazepam pack in that market, so a high figure is usually a larger pack rather than the same product.
Canada publishes no comparable public list price. For a delivered Canadian price on a licensed account, verify your licence — it takes about a minute.
Is there a generic Oxazepam in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
10 holders have a Canadian DIN containing Oxazepam, across 31 DINs, of which 9 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| APOTEX INC | 3 | 3 | APO-OXAZEPAM | Sourceable in Canada |
| LABORATOIRE RIVA INC. | 3 | 3 | RIVA-OXAZEPAM | Sourceable in Canada |
| PRO DOC LIMITEE | 3 | 3 | PRO-OXAZEPAM | Sourceable in Canada |
| BIOMED PHARMA | 6 | 0 | BIO-OXAZEPAM, OXPAM | No marketed DIN |
| LABORATOIRES CONFAB INC | 3 | 0 | OXAZEPAM 10MG TABLETS, OXAZEPAM 15MG TABLETS, OXAZEPAM 30MG TABLETS | No marketed DIN |
| NOVOPHARM LIMITED | 3 | 0 | NOVOXAPAM TAB 10MG, NOVOXAPAM TAB 15MG, NOVOXAPAM TAB 30MG | No marketed DIN |
| PHARMASCIENCE INC | 3 | 0 | PMS-OXAZEPAM TAB 10MG, PMS-OXAZEPAM TAB 15MG, PMS-OXAZEPAM TAB 30MG | No marketed DIN |
| WYETH-AYERST CANADA INC. | 3 | 0 | SERAX TABLETS 10MG, SERAX TABLETS 15MG, SERAX TABLETS 30MG | No marketed DIN |
| D.C. LABS LIMITED | 2 | 0 | OXAZEPAM TABLETS 15MG, OXAZEPAM TABLETS 30MG | No marketed DIN |
| WYETH LTD. | 2 | 0 | SERAX TAB 15MG, SERAX TAB 30MG | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 10 MG |
|---|---|
| Dosage form | TABLET |
| Route | ORAL |
| Pack configuration (monograph) | Bottles of 500 for 10 mg, 15 mg, and 30 mg tablets |
| Storage | null |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
Substance and classification
| Active substance | Oxazepam |
|---|---|
| ATC code | N05BA04 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 00497754 |
|---|---|
| DIN (unpadded, as printed on some documents) | 497754 |
| Brand name | PRO-OXAZEPAM |
| Generic / active ingredient | OXAZEPAM : 10 MG |
| Market authorization holder | PRO DOC LIMITEE |
| Health Canada schedule | TARGETED SUBSTANCES (CDSA IV) |
| ATC code | N05BA04 |
| ATC anatomical main group | N — Nervous system |
| ATC therapeutic subgroup | N05BA |
| Current status | MARKETED |
| Status date | 18-Jul-2023 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
How is it administered?
Adults: 30-120 mg daily in divided doses. Elderly/Debilitated: 5 mg once or twice daily. Use lowest effective dose for shortest duration. Taper gradually to discontinue.
Included because it drives pack selection and wastage. Consult the monograph.
Contraindications
Hypersensitivity to benzodiazepines, infants, history of glaucoma, and myasthenia gravis.
Warnings and precautions
Risk of addiction, abuse, and misuse. Concomitant use with opioids may cause respiratory depression/death. Risk of severe withdrawal symptoms. Risk of falls and fractures.
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
9 of 31 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| APO-OXAZEPAM | 10 MG | TABLET | APOTEX INC | MARKETED | 00402680 |
| APO-OXAZEPAM | 30 MG | TABLET | APOTEX INC | MARKETED | 00402737 |
| APO-OXAZEPAM | 15 MG | TABLET | APOTEX INC | MARKETED | 00402745 |
| PRO-OXAZEPAM | 30 MG | TABLET | PRO DOC LIMITEE | MARKETED | 00497770 |
| PRO-OXAZEPAM | 15 MG | TABLET | PRO DOC LIMITEE | MARKETED | 00497762 |
| RIVA-OXAZEPAM | 30 MG | TABLET | LABORATOIRE RIVA INC. | MARKETED | 00568414 |
| RIVA-OXAZEPAM | 10 MG | TABLET | LABORATOIRE RIVA INC. | MARKETED | 00568392 |
| RIVA-OXAZEPAM | 15 MG | TABLET | LABORATOIRE RIVA INC. | MARKETED | 00568406 |
| BIO-OXAZEPAM | 10 MG | TABLET | BIOMED PHARMA | CANCELLED POST MARKET | 02247177 |
| BIO-OXAZEPAM | 15 MG | TABLET | BIOMED PHARMA | CANCELLED POST MARKET | 02247178 |
2 · Same class — other molecules in ATC N05BA
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Lorazepam | APO-LORAZEPAM · ATIVAN · ATIVAN INJ 4MG/ML · ATIVAN INJECTION LIQ 4MG/ML · +21 more | 53 | 17 | Yes |
| Alprazolam | ALPRAZOLAM · ALPRAZOLAM TABLETS 0.25 · ALPRAZOLAM TABLETS 0.5MG · APO-ALPRAZ · +17 more | 50 | 13 | Yes |
| Oxazepam | APO-OXAZEPAM · BIO-OXAZEPAM · NOVOXAPAM TAB 10MG · NOVOXAPAM TAB 15MG · +17 more | 31 | 9 | Yes |
| Diazepam | BIO-DIAZEPAM · DIASTAT · DIAZEMULS · DIAZEPAM · +23 more | 38 | 8 | Yes |
| Bromazepam | ALTI-BROMAZEPAM 1.5MG TABLETS · ALTI-BROMAZEPAM 3MG TABLETS · ALTI-BROMAZEPAM 6MG TABLETS · APO-BROMAZEPAM · +14 more | 24 | 4 | Yes |
| Clorazepate Potassium | CLORAZEPATE · NOVO-CLOPATE CAP 15MG · NOVO-CLOPATE CAP 3.75MG · NOVO-CLOPATE CAP 7.5MG · +3 more | 9 | 3 | Yes |
| Clobazam | APO-CLOBAZAM · CLOBAZAM-10 · DOM-CLOBAZAM · FRISIUM TAB 10MG · +6 more | 10 | 2 | Yes |
| Chlordiazepoxide | CHLORDIAZEPOXIDE · CHLORDIAZEPOXIDE CAP 10MG · CHLORDIAZEPOXIDE CAP 5MG · CHLORDIAZEPOXYDE 25 CAP · +10 more | 16 | 1 | Yes |
| Ketazolam | LOFTRAN CAP 30MG | 1 | 0 | Not in Canada |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC N05B
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| N05BE | Buspirone | 25 | 7 |
| N05BB | Hydroxyzine | 29 | 5 |
| N05BC | Meprobamate | 7 | 0 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is PRO-OXAZEPAM called?
The same molecule, Oxazepam, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| Oxascand | Latin | Sweden |
| Serepax | Latin | Australia |
| Delipam | Latin | Sweden |
| Sobril | Latin | Iceland |
| APO-Oxazepam | Latin | Australia |
| Murelax | Latin | Australia |
| OXAZEPAM-WGR | Latin | Australia |
| Purata | Latin | South Africa |
| Oxazepam | Latin | South Africa |
| OXAZEPAM LÉČIVA | Latin | Slovakia |
| OXAZEPAM L��IVA | Latin | Czechia |
| Serepax Forte | Latin | South Africa |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.